{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T20:46:30Z","timestamp":1793652390532,"version":"4.5.1"},"reference-count":149,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T00:00:00Z","timestamp":1541030400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,12,6]],"date-time":"2018-12-06T00:00:00Z","timestamp":1544054400000},"content-version":"vor","delay-in-days":35,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuropharmacology"],"published-print":{"date-parts":[[2018,11]]},"DOI":"10.1016\/j.neuropharm.2018.02.018","type":"journal-article","created":{"date-parts":[[2018,2,21]],"date-time":"2018-02-21T17:26:51Z","timestamp":1519234011000},"page":"7-19","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":167,"special_numbering":"C","title":["Psychedelics: Where we are now, why we got here, what we must do"],"prefix":"10.1016","volume":"142","author":[{"given":"Sean J.","family":"Belouin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jack E.","family":"Henningfield","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neuropharm.2018.02.018_bib1","series-title":"A\u00a0Critical Review of Theories and Research Concerning Lysergic Acid Diethylamide (LSD) and Mental Health","author":"Abrahart","year":"1998"},{"key":"10.1016\/j.neuropharm.2018.02.018_bib2","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1080\/00223980.1955.9916156","article-title":"Lysergic acid diethylamide (LSD-25): I. Physiological and perceptual responses","volume":"39","author":"Abramson","year":"1955","journal-title":"J.\u00a0Psychol."},{"key":"10.1016\/j.neuropharm.2018.02.018_bib3","series-title":"v. O Centro Esp\u00edrita Beneficente Uni\u00e3o do Vegetal, et\u00a0al. Roberts Court","author":"Alberto","year":"2006"},{"key":"10.1016\/j.neuropharm.2018.02.018_bib4","series-title":"Over 20 Mental Health Organizations Call on House Leadership for Comprehensive Mental Health Reform","author":"American Psychiatric Association","year":"2015"},{"key":"10.1016\/j.neuropharm.2018.02.018_bib5","series-title":"Facts & Statistics [Fact Sheet]","author":"Anxiety and Depression Association of America","year":"2014"},{"key":"10.1016\/j.neuropharm.2018.02.018_bib6","doi-asserted-by":"crossref","first-page":"335","DOI":"10.31887\/DCNS.2006.8.3\/tban","article-title":"The role of serendipity in drug discovery","volume":"8","author":"Ban","year":"2006","journal-title":"Dialogues Clin. Neurosci."},{"key":"10.1016\/j.neuropharm.2018.02.018_bib7","first-page":"495","article-title":"Fifty years chlorpromazine: a historical perspective","volume":"3","author":"Ban","year":"2007","journal-title":"Neuropsychiatric Dis. Treat."},{"key":"10.1016\/j.neuropharm.2018.02.018_bib8","series-title":"Psychedelic Reflections","first-page":"143","article-title":"Mental liberation facilitated by the use of hallucinogenic drugs","author":"Bastiaans","year":"1983"},{"key":"10.1016\/j.neuropharm.2018.02.018_bib9","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1016\/j.mayocp.2014.09.003","article-title":"Mitigating the safety risks of drugs with a focus on opioids: are risk evaluation and mitigation strategies the answer?","volume":"89","author":"Brooks","year":"2014","journal-title":"Mayo Clin. Proc."},{"key":"10.1016\/j.neuropharm.2018.02.018_bib150","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1007\/s00213-017-4777-4","article-title":"Regulation of human research with LSD in the United States (1949-1987)","volume":"235","author":"Bonson","year":"2017","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.neuropharm.2018.02.018_bib10","article-title":"A\u00a0regulatory perspective on the evaluation of hallucinogen drugs for human use","author":"Calderon","year":"2017","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2018.02.018_bib11","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/S2215-0366(16)30065-7","article-title":"Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study","volume":"3","author":"Carhart-Harris","year":"2016","journal-title":"Lancet Psychiatry"},{"key":"10.1016\/j.neuropharm.2018.02.018_bib12","doi-asserted-by":"crossref","first-page":"15078","DOI":"10.1073\/pnas.1518393112","article-title":"Rising morbidity and mortality in midlife among white non-Hispanic Americans in the 21st century","volume":"112","author":"Case","year":"2015","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.neuropharm.2018.02.018_bib13","series-title":"Substance Abuse and Mental Health Services Administration","article-title":"Results from the 2015 national survey on drug use and health: detailed tables","author":"Center for Behavioral Health Statistics and Quality","year":"2016"},{"key":"10.1016\/j.neuropharm.2018.02.018_bib14","series-title":"Burden of Mental Illness","author":"Centers for Disease Control and Prevention","year":"2013"},{"key":"10.1016\/j.neuropharm.2018.02.018_bib15","series-title":"U.S. Department of Health and Human Services","article-title":"National diabetes Statistics report: estimates of diabetes and its burden in the United States, 2014","author":"Centers for Disease Control and Prevention","year":"2014"},{"key":"10.1016\/j.neuropharm.2018.02.018_bib16","series-title":"Suicide - Facts at a Glance","author":"Centers for Disease Control and Prevention","year":"2015"},{"key":"10.1016\/j.neuropharm.2018.02.018_bib17","series-title":"500 Cities: Local Data for Better Health","author":"Centers for Disease Control and Prevention","year":"2017"},{"key":"10.1016\/j.neuropharm.2018.02.018_bib18","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1177\/0269881113495119","article-title":"MDMA assisted psychotherapy found to have a large effect for chronic post-traumatic stress disorder","volume":"27","author":"Chabrol","year":"2013","journal-title":"J.\u00a0Psychopharmacol."},{"key":"10.1016\/j.neuropharm.2018.02.018_bib19","first-page":"A14","article-title":"The vital link between chronic disease and depressive disorders","volume":"2","author":"Chapman","year":"2005","journal-title":"Prev. Chronic Dis."},{"issue":"7\u20138","key":"10.1016\/j.neuropharm.2018.02.018_bib20","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1345\/aph.1E569","article-title":"FDA policy on unapproved drug products: past, present, and future","volume":"39","author":"Chhabra","year":"2005","journal-title":"Ann. Pharmacother."},{"key":"10.1016\/j.neuropharm.2018.02.018_bib21","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1177\/1529100614531398","article-title":"The impact of mental illness stigma on seeking and participating in mental health care","volume":"15","author":"Corrigan","year":"2014","journal-title":"Psychol. Sci. Publ. Interest"},{"issue":"Suppl.\u00a01","key":"10.1016\/j.neuropharm.2018.02.018_bib22","doi-asserted-by":"crossref","first-page":"S33","DOI":"10.1016\/j.drugalcdep.2009.05.019","article-title":"Signal detection in post-marketing surveillance for controlled substances","volume":"105","author":"Dasgupta","year":"2009","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.neuropharm.2018.02.018_bib23","article-title":"How MDMA Went from Club Drug to \u2018Breakthrough Therapy\u2019 Better known as \u2018ecstasy,\u2019 it's emerging as one of the most promising treatments for PTSD","author":"Dean","year":"2017","journal-title":"Wall St. J."},{"key":"10.1016\/j.neuropharm.2018.02.018_bib24","series-title":"Regulation of the Medical Use of Psychedelics and Marijuana","author":"Doblin","year":"2001"},{"key":"10.1016\/j.neuropharm.2018.02.018_bib25","author":"Drug Enforcement Administration"},{"key":"10.1016\/j.neuropharm.2018.02.018_bib26","author":"Drug Enforcement Administration"},{"key":"10.1016\/j.neuropharm.2018.02.018_bib27","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1093\/shm\/hkl039","article-title":"\u2018Hitting highs at rock bottom\u2019: LSD treatment for alcoholism, 1950\u20131970","volume":"19","author":"Dyck","year":"2006","journal-title":"Soc. Hist. Med."},{"key":"10.1016\/j.neuropharm.2018.02.018_bib28","first-page":"26","article-title":"Treating PTSD with MDMA-assisted psychotherapy: product development status and proposed design for phase 3 clinical trials","volume":"26","author":"Emerson","year":"2016","journal-title":"Multidiscip. Assoc. Psychedelic Stud."},{"key":"10.1016\/j.neuropharm.2018.02.018_bib29","author":"Florida Council for Community Mental Health"},{"key":"10.1016\/j.neuropharm.2018.02.018_bib30","doi-asserted-by":"crossref","first-page":"e24","DOI":"10.1200\/JOP.2012.000620","article-title":"Assessment of risk evaluation and mitigation strategies in oncology: summary of the oncology risk evaluation and mitigation strategies workshop","volume":"9","author":"Frame","year":"2013","journal-title":"J.\u00a0Oncol. Pract."},{"key":"10.1016\/j.neuropharm.2018.02.018_bib31","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1001\/archpsyc.1968.01740030074008","article-title":"On the use and abuse of LSD","volume":"18","author":"Freedman","year":"1968","journal-title":"Arch. Gen. Psychiatr."},{"key":"10.1016\/j.neuropharm.2018.02.018_bib32","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/0091-3057(86)90371-0","article-title":"Hallucinogenic drug research\u2013if so, so what? Symposium summary and commentary","volume":"24","author":"Freedman","year":"1986","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.neuropharm.2018.02.018_bib33","series-title":"The Mosaic of Contemporary Psychiatry in Perspective","first-page":"182","article-title":"LSD and psychiatry: a personal trip","author":"Freedman","year":"1992"},{"key":"10.1016\/j.neuropharm.2018.02.018_bib34","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1097\/NMD.0000000000000113","article-title":"Safety and efficacy of lysergic acid diethylamide-assisted psychotherapy for anxiety associated with life-threatening diseases","volume":"202","author":"Gasser","year":"2014","journal-title":"J.\u00a0Nerv. Ment. Dis."},{"key":"10.1016\/j.neuropharm.2018.02.018_bib35","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1177\/0269881116675513","article-title":"Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: a randomized double-blind trial","volume":"30","author":"Griffiths","year":"2016","journal-title":"J.\u00a0Psychopharmacol."},{"key":"10.1016\/j.neuropharm.2018.02.018_bib36","first-page":"343","volume":"xiv","author":"Grinspoon","year":"1979"},{"key":"10.1016\/j.neuropharm.2018.02.018_bib37","series-title":"A\u00a0Placebo-controlled, Randomized, Blinded, Dose Finding Phase 2 Pilot Safety Study of MDMA-assisted Therapy for Social Anxiety in Autistic Adults","author":"Grob","year":"2013"},{"key":"10.1016\/j.neuropharm.2018.02.018_bib38","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1001\/archgenpsychiatry.2010.116","article-title":"Pilot study of psilocybin treatment for anxiety in patients with advanced-stage cancer","volume":"68","author":"Grob","year":"2011","journal-title":"Arch. Gen. Psychiatr."},{"key":"10.1016\/j.neuropharm.2018.02.018_bib39","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1016\/j.biopsych.2005.06.038","article-title":"Psychological and cognitive effects of long-term peyote use among Native Americans","volume":"58","author":"Halpern","year":"2005","journal-title":"Biol. Psychiatr."},{"key":"10.1016\/j.neuropharm.2018.02.018_bib40","first-page":"1","article-title":"Constructing drug effects: a history of set and setting","volume":"3","author":"Hartogsohn","year":"2017","journal-title":"Drug\u00a0Sci. Policy Law"},{"key":"10.1016\/j.neuropharm.2018.02.018_bib42","series-title":"Drug Overdose Deaths in the United States, 1999-2015","author":"Hedegaard","year":"2017"},{"key":"10.1016\/j.neuropharm.2018.02.018_bib43","series-title":"Is Mental Health Declining in Th U.S.?","author":"Higgins","year":"2017"},{"key":"10.1016\/j.neuropharm.2018.02.018_bib44","series-title":"A\u00a0Dose of a Hallucinogen from a 'Magic Mushroom,' and Then Lasting Peace","author":"Hoffman","year":"2016"},{"key":"10.1016\/j.neuropharm.2018.02.018_bib45","first-page":"209","volume":"vol. xiii","author":"Hofmann","year":"1980"},{"key":"10.1016\/j.neuropharm.2018.02.018_bib46","series-title":"President's Symposium: Enhancing Research on Controlled Substances","author":"Howell","year":"2017"},{"key":"10.1016\/j.neuropharm.2018.02.018_bib47","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3003142","article-title":"Revolution stalled","volume":"4","author":"Hyman","year":"2012","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.neuropharm.2018.02.018_bib48","series-title":"The Obama Administration Just Made Medical Marijuana Research Easier","author":"Ingraham","year":"2015"},{"key":"10.1016\/j.neuropharm.2018.02.018_bib49","series-title":"Post by Former NIMH Director Thomas Insel: Mental Health Awareness Month: by the Numbers","author":"Insel","year":"2015"},{"key":"10.1016\/j.neuropharm.2018.02.018_bib50","series-title":"Effectiveness of the International Drug Control Treaties: Supplement to the Report of the International Narcotics Control Board for 1994","author":"International Narcotics Control Board","year":"1994"},{"issue":"Suppl.\u00a01","key":"10.1016\/j.neuropharm.2018.02.018_bib51","doi-asserted-by":"crossref","first-page":"S65","DOI":"10.1016\/j.drugalcdep.2009.08.006","article-title":"Risk management and post-marketing surveillance for the abuse of medications acting on the central nervous system: expert panel report","volume":"105","author":"Johanson","year":"2009","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.neuropharm.2018.02.018_bib52","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1177\/0269881108093587","article-title":"Human hallucinogen research: guidelines for safety","volume":"22","author":"Johnson","year":"2008","journal-title":"J.\u00a0Psychopharmacol."},{"key":"10.1016\/j.neuropharm.2018.02.018_bib53","series-title":"Science and Policy for the Twenty-first Century","first-page":"87","article-title":"Addiction and pregnancy","author":"Jones","year":"2007"},{"key":"10.1016\/j.neuropharm.2018.02.018_bib54","first-page":"381","volume":"vol. xxix","author":"Kamie\u0144ski","year":"2016"},{"key":"10.1016\/j.neuropharm.2018.02.018_bib55","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1176\/appi.ajp.2008.08010126","article-title":"Individual and societal effects of mental disorders on earnings in the United States: results from the national comorbidity survey replication","volume":"165","author":"Kessler","year":"2008","journal-title":"Am. J. Psychiatr."},{"key":"10.1016\/j.neuropharm.2018.02.018_bib56","first-page":"1","article-title":"The effect of changes in selected age-specific causes of death on non-hispanic white life expectancy between 2000 and 2014","author":"Kochanek","year":"2016","journal-title":"NCHS Data Brief"},{"key":"10.1016\/j.neuropharm.2018.02.018_bib57","series-title":"Addiction Treatment: Science and Policy for the Twenty-first Century","first-page":"1","article-title":"Drug addiction in America: challenges and opportunities","author":"Koop","year":"2007"},{"key":"10.1016\/j.neuropharm.2018.02.018_bib58","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1177\/0269881112439253","article-title":"Lysergic acid diethylamide (LSD) for alcoholism: meta-analysis of randomized controlled trials","volume":"26","author":"Krebs","year":"2012","journal-title":"J.\u00a0Psychopharmacol."},{"key":"10.1016\/j.neuropharm.2018.02.018_bib59","series-title":"The Santo Daime Church - the Protection of Freedom of Religion under International Law","author":"K\u00fcfner","year":"2007"},{"key":"10.1016\/j.neuropharm.2018.02.018_bib60","series-title":"Psilocybin-assisted Psychotherapy in the Management of Anxiety Associated with Stage IV Melanoma","author":"Kumar","year":"2008"},{"key":"10.1016\/j.neuropharm.2018.02.018_bib61","series-title":"Neuropsychedelia: the Revival of Hallucinogen Research since the Decade of the Brain","first-page":"336","author":"Langlitz","year":"2012"},{"key":"10.1016\/j.neuropharm.2018.02.018_bib62","volume":"vol. xxv","author":"Lee","year":"1992"},{"key":"10.1016\/j.neuropharm.2018.02.018_bib63","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1016\/j.janxdis.2011.01.002","article-title":"The discovery of chlordiazepoxide and the clinical introduction of benzodiazepines: half a century of anxiolytic drugs","volume":"25","author":"Lopez-Munoz","year":"2011","journal-title":"J.\u00a0Anxiety Disord."},{"key":"10.1016\/j.neuropharm.2018.02.018_bib64","series-title":"Timothy Leary, Pied Piper of Psychedelic 60's, Dies at 75","author":"Mansnerus","year":"1996"},{"key":"10.1016\/j.neuropharm.2018.02.018_bib65","series-title":"The Scientific Investigation of Ayahuasca: A Review of Past and Current Research","first-page":"65","author":"McKenna","year":"1998"},{"key":"10.1016\/j.neuropharm.2018.02.018_bib66","series-title":"Promoting Safe and Effective Drugs for 100 Years, FDA Consumer Magazine","author":"Meadows","year":"2006"},{"key":"10.1016\/j.neuropharm.2018.02.018_bib67","author":"Mental Health America"},{"key":"10.1016\/j.neuropharm.2018.02.018_bib68","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1663\/0013-0001(2003)057[0295:AEFTTO]2.0.CO;2","article-title":"COVER ARTICLE: archaeological evidence for the tradition of psychoactive plant use in the old world","volume":"57","author":"Merlin","year":"2003","journal-title":"Econ. Bot."},{"key":"10.1016\/j.neuropharm.2018.02.018_bib69","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1080\/02791072.1998.10399709","article-title":"Hallucinogenic drugs and plants in psychotherapy and shamanism","volume":"30","author":"Metzner","year":"1998","journal-title":"J.\u00a0Psychoact. Drugs"},{"key":"10.1016\/j.neuropharm.2018.02.018_bib71","author":"Mithoefer","year":"2011"},{"key":"10.1016\/j.neuropharm.2018.02.018_bib72","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1177\/0269881110378371","article-title":"The safety and efficacy of {+\/-}3,4-methylenedioxymethamphetamine-assisted psychotherapy in subjects with chronic, treatment-resistant posttraumatic stress disorder: the first randomized controlled pilot study","volume":"25","author":"Mithoefer","year":"2011","journal-title":"J.\u00a0Psychopharmacol."},{"key":"10.1016\/j.neuropharm.2018.02.018_bib73","series-title":"The Medical History of Psychedelic Drugs","author":"Multidisciplinary Association for Psychedelic Studies","year":"2007"},{"key":"10.1016\/j.neuropharm.2018.02.018_bib74","author":"Multidisciplinary Association for Psychedelic Studies"},{"key":"10.1016\/j.neuropharm.2018.02.018_bib75","author":"Multidisciplinary Association for Psychedelic Studies"},{"key":"10.1016\/j.neuropharm.2018.02.018_bib76","author":"Multidisciplinary Association for Psychedelic Studies"},{"key":"10.1016\/j.neuropharm.2018.02.018_bib77","series-title":"Pain Management and the Opioid Epidemic: Balancing Societal and Individual Benefits and Risks of Prescription Opioid Use","author":"National Academies of Sciences, E., and Medicine","year":"2017"},{"key":"10.1016\/j.neuropharm.2018.02.018_bib78","author":"National Alliance on Mental Illness"},{"key":"10.1016\/j.neuropharm.2018.02.018_bib79","series-title":"National Drug Threat Assessment","author":"National Drug Intelligence Center","year":"2011"},{"key":"10.1016\/j.neuropharm.2018.02.018_bib81","author":"National Institute of Drug Abuse"},{"key":"10.1016\/j.neuropharm.2018.02.018_bib80","author":"National Institute on Drug Abuse"},{"key":"10.1016\/j.neuropharm.2018.02.018_bib82","unstructured":"National Institute on Drug Abuse, What kinds of marijuana research does NIDA fund?, 2016. https:\/\/www.drugabuse.gov\/drugs-abuse\/marijuana\/marijuana-cannabinoid-research-nida, (Accessed; Accessed 21 February 2018)."},{"key":"10.1016\/j.neuropharm.2018.02.018_bib83","author":"National Institute of Mental Health (U.S.)"},{"key":"10.1016\/j.neuropharm.2018.02.018_bib84","author":"National Institute of Mental Health (U.S.), Major depression among adults"},{"key":"10.1016\/j.neuropharm.2018.02.018_bib85","author":"National Institute of Mental Health (U.S.)"},{"key":"10.1016\/j.neuropharm.2018.02.018_bib86","series-title":"Managed Care Pharmacy Practice","author":"Navarro","year":"2009"},{"key":"10.1016\/j.neuropharm.2018.02.018_bib87","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.pharmthera.2003.11.002","article-title":"Hallucinogens","volume":"101","author":"Nichols","year":"2004","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.neuropharm.2018.02.018_bib88","author":"Nobel Media AB 2014"},{"key":"10.1016\/j.neuropharm.2018.02.018_bib89","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pbio.1002047","article-title":"Illegal drugs laws: clearing a 50-year-old obstacle to research","volume":"13","author":"Nutt","year":"2015","journal-title":"PLoS Biol."},{"key":"10.1016\/j.neuropharm.2018.02.018_bib90","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1038\/nrn3530","article-title":"Effects of Schedule I drug laws on neuroscience research and treatment innovation","volume":"14","author":"Nutt","year":"2013","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.neuropharm.2018.02.018_bib91","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1177\/0269881112464827","article-title":"A\u00a0randomized, controlled pilot study of MDMA (+\/- 3,4-Methylenedioxymethamphetamine)-assisted psychotherapy for treatment of resistant, chronic post-traumatic stress disorder (PTSD)","volume":"27","author":"Oehen","year":"2013","journal-title":"J.\u00a0Psychopharmacol."},{"key":"10.1016\/j.neuropharm.2018.02.018_bib92","author":"Office of Disease Prevention and Health Promotion"},{"key":"10.1016\/j.neuropharm.2018.02.018_bib93","first-page":"20","article-title":"The economic burden of mental health care","volume":"40","author":"Pal","year":"2015","journal-title":"U.S. Pharm."},{"key":"10.1016\/j.neuropharm.2018.02.018_bib94","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1038\/nrd2094","article-title":"Drug development for CNS disorders: strategies for balancing risk and reducing attrition","volume":"6","author":"Pangalos","year":"2007","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.neuropharm.2018.02.018_bib95","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1016\/j.neuron.2014.10.007","article-title":"Improving and accelerating drug development for nervous system disorders","volume":"84","author":"Pankevich","year":"2014","journal-title":"Neuron"},{"key":"10.1016\/j.neuropharm.2018.02.018_bib96","series-title":"Indigenous Religious Traditions","article-title":"Peyote in native american traditions","author":"Parker","year":"2013"},{"key":"10.1016\/j.neuropharm.2018.02.018_bib97","series-title":"FDA Agrees to New Trials for Ecstasy as Relief for PTSD Patients","author":"Philipps","year":"2016"},{"key":"10.1016\/j.neuropharm.2018.02.018_bib98","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1177\/0269881117691453","article-title":"The Association of Psychedelic Use and Opioid Use Disorders Among Illicit Users in the United States","volume":"31","author":"Pisano","year":"2017","journal-title":"J.\u00a0Psychopharmacol."},{"key":"10.1016\/j.neuropharm.2018.02.018_bib99","series-title":"The Trip Treatment","author":"Pollan","year":"2015"},{"key":"10.1016\/j.neuropharm.2018.02.018_bib100","series-title":"Draft Interim Report","author":"President's Commission on Combating Drug Addiction and the Opioid Crisis","year":"2017"},{"key":"10.1016\/j.neuropharm.2018.02.018_bib101","series-title":"Secretary Price Announces HHS Strategy for Fighting Opioid Crisis","author":"Price","year":"2017"},{"key":"10.1016\/j.neuropharm.2018.02.018_bib102","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1124\/jpet.103.049882","article-title":"Human pharmacology of ayahuasca: subjective and cardiovascular effects, monoamine metabolite excretion, and pharmacokinetics","volume":"306","author":"Riba","year":"2003","journal-title":"J.\u00a0Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.neuropharm.2018.02.018_bib103","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.15585\/mmwr.mm6450a3","article-title":"Increases in drug and opioid overdose Deaths\u2013United States, 2000-2014","volume":"64","author":"Rudd","year":"2016","journal-title":"MMWR Morb. Mortal. Wkly. Rep."},{"key":"10.1016\/j.neuropharm.2018.02.018_bib104","doi-asserted-by":"crossref","first-page":"e73","DOI":"10.1016\/j.amepre.2015.05.031","article-title":"2010 national and state costs of excessive alcohol consumption","volume":"49","author":"Sacks","year":"2015","journal-title":"Am. J. Prev. Med."},{"key":"10.1016\/j.neuropharm.2018.02.018_bib105","series-title":"Addiction Treatment: Science and Policy for the Twenty-first Century","first-page":"147","article-title":"In praise of stigma","author":"Satel","year":"2007"},{"key":"10.1016\/j.neuropharm.2018.02.018_bib106","author":"Schnoll"},{"key":"10.1016\/j.neuropharm.2018.02.018_bib107","series-title":"End the Ban on Psychoactive Drug Research","author":"Scientific American Editors","year":"2014"},{"key":"10.1016\/j.neuropharm.2018.02.018_bib108","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1212\/01.wnl.0000219761.05466.43","article-title":"Response of cluster headache to psilocybin and LSD","volume":"66","author":"Sewell","year":"2006","journal-title":"Neurology"},{"key":"10.1016\/j.neuropharm.2018.02.018_bib109","series-title":"Psychoactive Drugs: Tolerance and Sensitization","first-page":"115","article-title":"Pharmacological conditioning and drug effects","author":"Siegel","year":"1989"},{"key":"10.1016\/j.neuropharm.2018.02.018_bib110","series-title":"Hallucinations: Behavior, Experience, and Theory","first-page":"322","year":"1975"},{"key":"10.1016\/j.neuropharm.2018.02.018_bib111","series-title":"Library of Parliament, Canada","article-title":"The history and development of the leading international drug control conventions: prepared for the senate special committee on illegal drugs","author":"Sinha","year":"2001"},{"key":"10.1016\/j.neuropharm.2018.02.018_bib112","series-title":"How Psychedelic Drugs Can Help Patients Face Death","author":"Slater","year":"2012"},{"key":"10.1016\/j.neuropharm.2018.02.018_bib113","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.drugalcdep.2004.04.011","article-title":"Debating the controlled substances Act","volume":"76","author":"Spillane","year":"2004","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.neuropharm.2018.02.018_bib114","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1016\/S0376-8716(03)00096-6","article-title":"Keeping the lid on: a century of drug regulation and control","volume":"70","author":"Spillane","year":"2003","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.neuropharm.2018.02.018_bib115","doi-asserted-by":"crossref","first-page":"E109","DOI":"10.5888\/pcd11.130293","article-title":"Contribution of excessive alcohol consumption to deaths and years of potential life lost in the United States","volume":"11","author":"Stahre","year":"2014","journal-title":"Prev. Chronic Dis."},{"key":"10.1016\/j.neuropharm.2018.02.018_bib116","series-title":"Encyclopedia of Psychopharmacology","first-page":"1392","author":"Stolerman","year":"2010"},{"key":"10.1016\/j.neuropharm.2018.02.018_bib117","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1097\/00005053-199503000-00002","article-title":"Hallucinogenic drugs in psychiatric research and treatment. Perspectives and prospects","volume":"183","author":"Strassman","year":"1995","journal-title":"J.\u00a0Nerv. Ment. Dis."},{"key":"10.1016\/j.neuropharm.2018.02.018_bib118","series-title":"Native American Church. The Encyclopedia of Oklahoma History and Culture","author":"Swan","year":"2009"},{"key":"10.1016\/j.neuropharm.2018.02.018_bib119","first-page":"1214","article-title":"Reviving research into psychedelic drugs","volume":"367","author":"The Lancet","year":"2006","journal-title":"Lancet"},{"key":"10.1016\/j.neuropharm.2018.02.018_bib120","author":"The Pew Charitable Trusts, John D. and Catherine T. MacArthur Foundation"},{"key":"10.1016\/j.neuropharm.2018.02.018_bib121","author":"The Pew Charitable Trusts, John D. and Catherine T. MacArthur Foundation"},{"key":"10.1016\/j.neuropharm.2018.02.018_bib122","series-title":"President Donald J. Trump is Taking Action on Drug Addiction and the Opioid Crisis","author":"The White House","year":"2017"},{"key":"10.1016\/j.neuropharm.2018.02.018_bib123","author":"Traditional Indian religious use of peyote"},{"key":"10.1016\/j.neuropharm.2018.02.018_bib124","series-title":"International Drug Control: 100 Years of Success?, Drug Policy Briefing","author":"Transnational Institute","year":"2006"},{"key":"10.1016\/j.neuropharm.2018.02.018_bib125","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.drugpo.2006.11.001","article-title":"The globalization of ayahuasca: harm reduction or benefit maximization?","volume":"19","author":"Tupper","year":"2008","journal-title":"Int. J. Drug Pol."},{"key":"10.1016\/j.neuropharm.2018.02.018_bib126","author":"United Nations"},{"key":"10.1016\/j.neuropharm.2018.02.018_bib154","author":"University of Maryland Center for Substance Abuse Research, LSD"},{"key":"10.1016\/j.neuropharm.2018.02.018_bib127","author":"University of Maryland Center for Substance Abuse Research, Psilocybin\/Psilocyn"},{"key":"10.1016\/j.neuropharm.2018.02.018_bib128","author":"U.S. Congress"},{"key":"10.1016\/j.neuropharm.2018.02.018_bib129","author":"U.S. Department of Health and Human Services"},{"key":"10.1016\/j.neuropharm.2018.02.018_bib130","series-title":"U.S. Department of Health and Human Services","article-title":"Facing addiction in America: the Surgeon General's report on alcohol, drugs, and health","author":"U.S. Department of Health and Human Services Office of the Surgeon General","year":"2016"},{"key":"10.1016\/j.neuropharm.2018.02.018_bib131","author":"U.S. Department of Veterans Affairs"},{"key":"10.1016\/j.neuropharm.2018.02.018_bib132","series-title":"U.S. Department of Health and Human Services, F. a. D. A","article-title":"Risk evaluation and mitigation strategies: modifications and revisions: guidance for industry","author":"U.S. Food and Drug Administration","year":"2015"},{"key":"10.1016\/j.neuropharm.2018.02.018_bib133","series-title":"U.S. Department of Health and Human Services, F. a. D. A","article-title":"Expanded access to investigational drugs for treatment use - questions and answers: guidance for industry","author":"U.S. Food and Drug Administration","year":"2016"},{"key":"10.1016\/j.neuropharm.2018.02.018_bib134","series-title":"U.S. Department of Health and Human Services, F. a. D. A","article-title":"FDA's application of statuatory factors in determining when a REMS is necessary: guidance for industry: draft guidance","author":"U.S. Food and Drug Administration","year":"2016"},{"key":"10.1016\/j.neuropharm.2018.02.018_bib135","series-title":"U.S. Department of Health and Human Services, F. a. D. A","article-title":"Assessment of abuse potential of drugs: guidance for industry","author":"U.S. Food and Drug Administration","year":"2017"},{"key":"10.1016\/j.neuropharm.2018.02.018_bib136","author":"U.S. Food and Drug Administration"},{"key":"10.1016\/j.neuropharm.2018.02.018_bib137","author":"U.S. Food and Drug Administration"},{"key":"10.1016\/j.neuropharm.2018.02.018_bib138","author":"U.S. Food and Drug Administration"},{"key":"10.1016\/j.neuropharm.2018.02.018_bib139","author":"Volkow"},{"key":"10.1016\/j.neuropharm.2018.02.018_bib140","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1056\/NEJMsr1706626","article-title":"The role of science in addressing the opioid crisis","volume":"377","author":"Volkow","year":"2017","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.neuropharm.2018.02.018_bib141","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1136\/bmj.331.7520.795","article-title":"Nobel prize is awarded to doctors who discovered H pylori","volume":"331","author":"Watts","year":"2005","journal-title":"BMJ"},{"key":"10.1016\/j.neuropharm.2018.02.018_bib142","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1017\/S1461145713000345","article-title":"The current development of CNS drug research","volume":"16","author":"Wegener","year":"2013","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.neuropharm.2018.02.018_bib143","series-title":"The Dr. Who Drank Infectious Broth, Gave Himself an Ulcer, and Solved a Medical Mystery","author":"Weintraub","year":"2010"},{"key":"10.1016\/j.neuropharm.2018.02.018_bib144","series-title":"Studying the Brain Mechanisms behind Drug Addiction and Overconsumption of Sweet, Fatty Food","author":"West","year":"2016"},{"key":"10.1016\/j.neuropharm.2018.02.018_bib145","first-page":"1","article-title":"How will DEA affect your clinical study?","volume":"7","author":"Woodworth","year":"2011","journal-title":"J.\u00a0Clin. Res. Best Pract."},{"key":"10.1016\/j.neuropharm.2018.02.018_bib146","series-title":"The World Health Report - Mental Health: New Understanding, New Hope","author":"World Health Organization","year":"2001"},{"key":"10.1016\/j.neuropharm.2018.02.018_bib147","series-title":"Mental Health Action Plan 2013-2020","author":"World Health Organization","year":"2013"},{"key":"10.1016\/j.neuropharm.2018.02.018_bib148","series-title":"Depression and Other Common Mental Disorders: Global Health Estimates","author":"World Health Organization","year":"2017"},{"key":"10.1016\/j.neuropharm.2018.02.018_bib149","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s40545-016-0051-0","article-title":"Don't sell out safety: a call to preserve risk evaluation and mitigation strategies to reduce harm to patients and the public in the U.S","volume":"9","author":"Worthy","year":"2016","journal-title":"J.\u00a0Pharm. Policy Pract."}],"container-title":["Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390818300753?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390818300753?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,8,14]],"date-time":"2022-08-14T17:29:26Z","timestamp":1660498166000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0028390818300753"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11]]},"references-count":149,"alternative-id":["S0028390818300753"],"URL":"https:\/\/doi.org\/10.1016\/j.neuropharm.2018.02.018","relation":{},"ISSN":["0028-3908"],"issn-type":[{"value":"0028-3908","type":"print"}],"subject":[],"published":{"date-parts":[[2018,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Psychedelics: Where we are now, why we got here, what we must do","name":"articletitle","label":"Article Title"},{"value":"Neuropharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neuropharm.2018.02.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}